MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Monday, February 20, 2012

Ocrelizumab Research known by the OPERA Study


There are many, who will read this, who may be eligible to join the OPERA study near you.
Look into it.


 Results of a phase 2 trial of ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis (MS) show that both doses studied significantly reduced the total number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) at 24 weeks vs placebo.
Both the 600-mg and 2000-mg doses studied reduced clinical relapses, with no apparent separation between doses, and extension data in this report out to 48 weeks suggested sustained efficacy, the researchers note.
"The similarly pronounced effects of B-cell depletion with both ocrelizumab doses on MRI and relapse-related outcomes support a role for B-cells in disease pathogenesis and warrant further assessment in large, long-term trials," the researchers, with first author Ludwig Kappos, MD, from University Hospital, Basel, Switzerland, conclude.
The results were published online November 1 in The Lancet.
The primary analysis of this study at 24 weeks was presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, in October 2010, and reported by Medscape Medical News at that time. Data to 72 weeks were presented at the 21st Meeting of the European Neurological Society, and most recently, results out to 96 weeks were presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS) in Amsterdam, the Netherlands.
The reduction in clinical relapses seen with treatment was maintained from week 24 to week 96, with subsequent infusions at 24-week intervals. In addition, patients who switched from placebo to ocrelizumab at the end of the blinded phase of the trial had similar reductions in the clinical measures of disease.
"Phase 3 has started; we are recruiting in 1 study for primary progressive [MS] and 2 studies...for relapsing forms of [MS]," David Leppert, MD, who is also from University Hospitals Basel, and F. Hoffman-La Roche Ltd, and who presented the results at ECTRIMS/ACTRIMS, told Medscape Medical News.
The phase 3 program, called ORCHESTRA, includes the 2 relapsing-remitting MS trials, called OPERA I and II, and the primary progressive MS trial, called ORATORIO.




..Comments for each blog posting are always appreciated. 
     Please use the link found below, to leave comments..
 .. All comments are moderated to reduce SPAM and bad language ..
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 Click here to: REGISTER - For our MS weekly e-Newsletter
"Providing You with 'MS Views and News', IS What We Do"   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
..............................

No comments: